TOFACITINIB

tofacitinib 5 mg tablet, 56

TOFACITINIB (10511F)

tofacitinib 5 mg tablet, 56
10511F
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 56 # of repeats: 5 DPMQ: $1,155.38 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Xeljanz